Screener
Arcus Biosciences RCUS Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total non-operating income, net | 5 | 8 | 11 | 18 |
| Income (loss) before income taxes | (91) | — | (219) | (112) |
| Income tax expense | — | — | — | — |
| Net income (loss) | $(91) | — | $(219) | $(112) |
| Net income (loss) per share: | ||||
| Basic | $(0.72) | — | $(1.74) | $(1.09) |
| Diluted | $(0.72) | — | $(1.74) | $(1.09) |
| Shares used to compute net income (loss) per share: |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's net income?
- Arcus Biosciences (RCUS) reported net income of -$91M in Q2 2026.
- What is the long-term trend for Arcus Biosciences's net income?
- Over 4 years (2021 to 2025), Arcus Biosciences's net income has grown at a 60.6% compound annual growth rate (CAGR), from $53M to -$353M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Arcus Biosciences's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude